KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Operating Leases (2020 - 2026)

Aquestive Therapeutics has reported Operating Leases over the past 6 years, most recently at $4.3 million for Q4 2025.

  • For Q4 2025, Operating Leases fell 12.7% year-over-year to $4.3 million; the TTM value through Dec 2025 reached $4.3 million, down 12.7%, while the annual FY2025 figure was $4.3 million, 12.7% down from the prior year.
  • Operating Leases for Q4 2025 was $4.3 million at Aquestive Therapeutics, down from $4.5 million in the prior quarter.
  • Over five years, Operating Leases peaked at $6.0 million in Q2 2023 and troughed at $1.7 million in Q1 2022.
  • A 5-year average of $4.3 million and a median of $5.0 million in 2022 define the central range for Operating Leases.
  • Biggest five-year swings in Operating Leases: crashed 35.1% in 2022 and later skyrocketed 233.68% in 2023.
  • Year by year, Operating Leases stood at $1.9 million in 2021, then skyrocketed by 161.31% to $5.1 million in 2022, then increased by 6.18% to $5.4 million in 2023, then decreased by 7.98% to $5.0 million in 2024, then dropped by 12.7% to $4.3 million in 2025.
  • Business Quant data shows Operating Leases for AQST at $4.3 million in Q4 2025, $4.5 million in Q3 2025, and $5.2 million in Q2 2025.